The decision positions LANGLARA as only the fourth insulin glargine product available in the US market, joining established products commercialized by Novo Nordisk, Sanofi and Eli Lilly.
ADVERTISEMENT
Sunshine Lake Pharma breaks US barriers with historic FDA approval for LANGLARA
Related Articles
UAE e-invoicing deadline extended: What this means
UAE pushed back deadline for companies to appoint approved e-invoicing providers Dubai: UAE businesses now have extra time to prepare for the country’s mandatory e-invoicing system after authorities extended the deadline for appointing an accredited service provider (ASP) to October 30, 2026. The Ministry of Finance announced the extension as compa…
GULF NEWS
May 11, 2026
Climate Engineering Moves From Science Fiction To Strategic Concern
(MENAFN - AzerNews) Ulviyya Poladova Read more In the last few decades, humanity's growing influence over nature has become one of the defining themes of the modern age. From genetic modification to ...
Menafn
May 11, 2026
ADVERTISEMENT